HNGE Delivers Record Results: Revenue Up 51%, Margins Climb, and Member Growth Accelerates
Record Revenue Growth and Expanding Margins Highlight Strong Execution
Hinge Health (NYSE:HNGE) closed 2025 with remarkable momentum, reporting a 51% year-over-year revenue increase to $587.9 million, up from $390.4 million in 2024. Both GAAP and non-GAAP gross margins improved, reaching 80% and 83% for the year, respectively—each about three to six points higher than last year. Q4 showcased particular strength, with revenue rising 46% to $170.7 million and a non-GAAP gross margin of 85%.
CEO Daniel Perez attributes this performance to a record selling season, the highest win rates in company history, and a surge in eligible lives added. Non-GAAP income from operations for the full year swung to $119.46 million, compared to a loss of $26.10 million last year, while operating cash flows and free cash flow soared over 250% and 297% year-over-year.
Strong Commercial Momentum: Clients, Members, and Contracted Lives Accelerate
Growth was broad-based across key business metrics. The number of clients surged by 25% to 2,830, contracted lives climbed to 25 million (up from 20 million), and members grew by nearly half to 782,890. Eligible lives averaged 20.1 million for the year, and the company’s yield—a measure of member adoption—reached 3.9%, up 50 basis points.
| Key Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue ($M) | 587.90 | 390.40 | +51% |
| GAAP Gross Margin | 80% | 77% | +3 pts |
| Non-GAAP Gross Margin | 83% | 78% | +5 pts |
| Clients | 2,830 | 2,256 | +25% |
| Members | 782,890 | 532,326 | +47% |
| Contracted Lives | 25M | 20M | +25% |
| Free Cash Flow ($M) | 179.60 | 45.23 | +297% |
Profitability and Cash Generation Surpass Expectations
HNGE’s profitability metrics demonstrated ongoing operational improvement. Operating cash flow for the year rocketed 250% to $171.4 million, and free cash flow margin rose to 31%, compared to just 12% last year. The Rule of 40—a blended measure of growth plus free cash flow margin—reached an impressive 81, up from 45 in 2024, signaling that Hinge is delivering well above typical SaaS benchmarks.
GAAP income from operations was deeply impacted by non-cash charges (driven largely by stock-based compensation), but on a non-GAAP basis, the swing to positive operating income is a striking turnaround for investors tracking Hinge Health’s long-term path to scale and profitability.
Share Buyback and Robust Balance Sheet Add to Investor Appeal
During Q4, HNGE repurchased $65 million worth of Class A shares as part of a $250 million buyback authorization. Year-end cash, cash equivalents, marketable securities, and restricted cash totaled $478.8 million, offering a substantial cushion and strategic flexibility for further innovation and growth initiatives.
2026 Guidance Points to Continued Strength
Hinge Health projects Q1 2026 revenue between $171–$173 million, a 39% midpoint year-over-year growth, and targets full-year revenue of $732–$742 million—about 25% growth at the midpoint. Non-GAAP operating margins are expected to rise, with anticipated non-GAAP income from operations of $151–$156 million, up 29% over 2025.
| 2026 Guidance | Q1 2026 | Full Year 2026 |
|---|---|---|
| Revenue ($M) | 171–173 | 732–742 |
| Revenue Growth (YoY) | +39% | +25% |
| Non-GAAP Op. Income ($M) | 30–32 | 151–156 |
| Non-GAAP Op. Margin | 18% | 21% |
Key Takeaway: Momentum Positions HNGE for Technology-Driven Expansion
From a business fundamentals perspective, HNGE’s quarter and year were characterized by rapid top-line and bottom-line improvement, underpinned by growing demand, expanding margins, and strong cash generation. The adoption of AI-powered care models and further automation have improved scalability and member outcomes, helping cement Hinge Health as a leader in digital musculoskeletal care. Investors may want to track further updates on margin expansion, client wins, and the pace of buybacks as Hinge Health heads into 2026 with momentum and a cash-rich balance sheet.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI